Skip to content

Clinical Study of Ultrasound-guided Percutaneous Microwave ablation for Hyperthyroidism in Children

Efficacy and safety of Ultrasound-guided Percutaneous Microwave ablation for Hyperthyroidism in Children: a pilot study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062125
Enrollment
Unknown
Registered
2022-07-23
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperthyroidism

Interventions

Sponsors

Beijing Children's Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Age from 3 to 18 years old; 2.Meet the diagnostic criteria of clinical hyperthyroidism: a. Signs and symptoms of clinical hypermetabolism; b. Goiter and/or nodule; c. Serum thyroid function test: triiodothyronine Baseline data collection of children with hyperthyroidism in hyperthyroidism (TT3), total thyroxine (TT4), free triiodothyronine (FT3) and free thyroxine (FT4) levels Group microwave ablation parameters, ablation volume complications, serum thyroid function level, oral ATD, adverse event screening period, treatment period, recurrence rate increased, thyroid-stimulating hormone (TSH) level decreased (according to the standards adopted by the Laboratory Department of Beijing Children's Hospital Affiliated to Capital Medical University, The reference interval to define normal thyroid function in serum is: TT31.078-3.388nmol/L; TT451.5-173.8nmol/L; FT32.75-9.90pmol/L; FT48.37-29.6pmol/L; TSH0.4- 6.0mIU/L); 3.After receiving regular ATD treatment for 18-24 months, the hyperthyroidism continued to be unable to reduce or stop the drug; 4.The child had poor medication compliance, and the serum thyroid function level could not maintain a stable state; 5.recurrence after ATD treatment was discontinued; 6.the child could not tolerate adverse drug reactions, or the adverse drug reactions persisted; 7.the goiter progressively worsened during regular drug treatment, and symptoms of compression appeared; 8.patients with Children and/or guardians refused to undergo radioactive 131I therapy or thyroid surgery; 9.patients with thyroid nodules were confirmed to be benign nodules by biopsy; 10.bilateral vocal cord movements were normal in electronic laryngoscopy.

Exclusion criteria

Exclusion criteria: 1.severe cardiovascular disease, liver and kidney insufficiency, etc.; 2.severe coagulation dysfunction; 3.a history of neck radiation exposure or a family history of thyroid cancer; 4.bilateral vocal cord dysfunction; 5.Active infiltrative exophthalmos.

Design outcomes

Primary

MeasureTime frame
Remission rate;

Secondary

MeasureTime frame
Postoperative improvement in symptoms of hyperthyroidism;Postoperative antithyroid drug reduction or withdrawal time;Hyperthyroidism recurrence;Complication rate;

Countries

China

Contacts

Public ContactShi Wenyuan

Beijing Children's Hospital Affiliated to Capital Medical University

sherry818@163.com+86 13701290337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026